Industry News (Patents and Technology)

Patent Issued for Use of PSA in Prostate Cancer Vaccine

Published in Cancer Weekly, March 15th, 1999

Jenner Biotherapies, San Ramon, California, announced the allowance of claims in the United States covering the use of recombinant prostate specific antigen (PSA) in the immunotherapy of patients with prostate cancer.

The allowed claims cover not only the use of recombinant PSA, but also the use of viral constructs containing cDNA encoding PSA and the use of naked DNA for vaccine therapy. PSA is a key antigen currently under clinical investigation by a number of biotechnology and pharmaceutical companies in vaccines for therapy of prostate cancer.

"PSA is an ideal antigen for use in the development of vaccines for therapy of prostate cancer," said...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-03-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry